Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375–2390 (2016).
Swerdlow, S. H. & Cook, J. R. As the world turns, evolving lymphoma classifications-past, present and future. Hum. Pathol. https://doi.org/10.1016/j.humpath.2019.08.019 (2019).
Lai, Y., Wei, X., Lin, S., Qin, L., Cheng, L. & Li, P. Current status and perspectives of patient-derived xenograft models in cancer research. J. Hematol. Oncol. 10, 106 (2017).
Sugimoto, K., Hayakawa, F., Shimada, S., Morishita, T., Shimada, K., Katakai, T. et al. Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. Sci. Rep. 5, 13054 (2015).
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A. et al. The public repository of xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell 29, 574–586 (2016).
Chapuy, B., Cheng, H., Watahiki, A., Ducar, M. D., Tan, Y., Chen, L. et al. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood 127, 2203–2213 (2016).
Burack, W. R., Spence, J. M., Spence, J. P., Spence, S. A., Rock, P. J., Shenoy, G. N. et al. Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment. Blood Adv. 1, 1263–1273 (2017).
Zhang, L., Nomie, K., Zhang, H., Bell, T., Pham, L., Kadri, S. et al. B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy. Clin. Cancer Res. 23, 4212–4223 (2017).
Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309–322 (2012).
Shain, K. H., Dalton, W. S. & Tao, J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene 34, 4673–4682 (2015).
McMillin, D. W., Negri, J. M. & Mitsiades, C. S. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov. 12, 217–228 (2013).
Prukova, D., Andera, L., Nahacka, Z., Karolova, J., Svaton, M., Klanova, M. et al. Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin. Cancer Res. 25, 4455–4465 (2019).
Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 378, 1396–1407 (2018).
Pasqualucci, L. & Dalla-Favera, R. Genetics of diffuse large B-cell lymphoma. Blood 131, 2307–2319 (2018).
Reddy, A., Zhang, J., Davis, N. S., Moffitt, A. B., Love, C. L., Waldrop, A. et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell 171, 481–494.e415 (2017).
Dubois, S., Viailly, P. J., Mareschal, S., Bohers, E., Bertrand, P., Ruminy, P. et al. Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study. Clin Cancer Res. 22, 2919–2928 (2016).
Karube, K., Enjuanes, A., Dlouhy, I., Jares, P., Martin-Garcia, D., Nadeu, F. et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia 32, 675–684 (2018).
Pasqualucci, L., Trifonov, V., Fabbri, G., Ma, J., Rossi, D., Chiarenza, A. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830–837 (2011).
Zhang, J., Grubor, V., Love, C. L., Banerjee, A., Richards, K. L., Mieczkowski, P. A. et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA. 110, 1398–1403 (2013).
Lohr, J. G., Stojanov, P., Lawrence, M. S., Auclair, D., Chapuy, B., Sougnez, C. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. USA. 109, 3879–3884 (2012).
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298–303 (2011).
Zhang, J., Jima, D., Moffitt, A. B., Liu, Q., Czader, M., Hsi, E. D. et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood 123, 2988–2996 (2014).
Bea, S., Valdes-Mas, R., Navarro, A., Salaverria, I., Martin-Garcia, D., Jares, P. et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc. Natl Acad. Sci. USA. 110, 18250–18255 (2013).
Yang, P., Zhang, W., Wang, J., Liu, Y., An, R. & Jing, H. Genomic landscape and prognostic analysis of mantle cell lymphoma. Cancer Gene Ther. https://doi.org/10.1038/s41417-018-0022-5 (2018).
Royo, C., Salaverria, I., Hartmann, E. M., Rosenwald, A., Campo, E. & Beà, S. The complex landscape of genetic alterations in mantle cell lymphoma. Semin. Cancer Biol. 21, 322–334 (2011).
Wu, C., de Miranda, N. F., Chen, L., Wasik, A. M., Mansouri, L., Jurczak, W. et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. Oncotarget 7, 38180–38190 (2016).
Ahmed, M., Zhang, L., Nomie, K., Lam, L. & Wang, M. Gene mutations and actionable genetic lesions in mantle cell lymphoma. Oncotarget 7, 58638–58648 (2016).
Crescenzo, R., Abate, F., Lasorsa, E., Tabbo, F., Gaudiano, M., Chiesa, N. et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 27, 516–532 (2015).
Larose, H., Prokoph, N., Matthews, J. D., Schlederer, M., Högler, S., Alsulami, A. F. et al. Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. Haematologica 106, 1693–1704 (2021).
Odejide, O., Weigert, O., Lane, A. A., Toscano, D., Lunning, M. A., Kopp, N. et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123, 1293–1296 (2014).
Palomero, T., Couronné, L., Khiabanian, H., Kim, M. Y., Ambesi-Impiombato, A., Perez-Garcia, A. et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat. Genet. 46, 166–170 (2014).
Sakata-Yanagimoto, M., Enami, T., Yoshida, K., Shiraishi, Y., Ishii, R., Miyake, Y. et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat. Genet. 46, 171–175 (2014).
Vallois, D., Dobay, M. P., Morin, R. D., Lemonnier, F., Missiaglia, E., Juilland, M. et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood 128, 1490–1502 (2016).
Watatani, Y., Sato, Y., Miyoshi, H., Sakamoto, K., Nishida, K., Gion, Y. et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia 33, 2867–2883 (2019).
Dave, S. S., Fu, K., Wright, G. W., Lam, L. T., Kluin, P., Boerma, E. J. et al. Molecular diagnosis of Burkitt’s lymphoma. N. Engl J. Med. 354, 2431–2442 (2006).
Love, C., Sun, Z., Jima, D., Li, G., Zhang, J., Miles, R. et al. The genetic landscape of mutations in Burkitt lymphoma. Nat. Genet. 44, 1321–1325 (2012).
López, C., Kleinheinz, K., Aukema, S. M., Rohde, M., Bernhart, S. H., Hübschmann, D. et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat. Commun. 10, 1459 (2019).
Panea, R. I., Love, C. L., Shingleton, J. R., Reddy, A., Bailey, J. A., Moormann, A. M. et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood 134, 1598–1607 (2019).
Penther, D., Viailly, P. J., Latour, S., Etancelin, P., Bohers, E., Vellemans, H. et al. A recurrent clonally distinct Burkitt lymphoma case highlights genetic key events contributing to oncogenesis. Genes Chromosomes Cancer 58, 595–601 (2019).
Richter, J., Schlesner, M., Hoffmann, S., Kreuz, M., Leich, E., Burkhardt, B. et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat. Genet. 44, 1316–1320 (2012).
Schmitz, R., Young, R. M., Ceribelli, M., Jhavar, S., Xiao, W., Zhang, M. et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490, 116–120 (2012).
Wagener, R., Seufert, J., Raimondi, F., Bens, S., Kleinheinz, K., Nagel, I. et al. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood 133, 962–966 (2019).
Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: Genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).
Tibshirani, R. & Wang, P. Spatial smoothing and hot spot detection for CGH data using the fused lasso. Biostatistics 9, 18–29 (2008).
Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize Implements and enhances circular visualization in R. Bioinformatics 30, 2811–2812 (2014).
Keša, P., Pokorná, E., Grajciarová, M., Tonar, Z., Vočková, P., Trochet, P. et al. Quantitative in vivo monitoring of hypoxia and vascularization of patient-derived murine xenografts of mantle cell lymphoma using photoacoustic and ultrasound imaging. Ultrasound Med. Biol. 47, 1099–1107 (2021).
Kolinko, Y., Malečková, A., Kochová, P., Grajciarová, M., Blassová, T., Kural, T. et al. Using virtual microscopy for the development of sampling strategies in quantitative histology and design-based stereology. Anat. Histol. Embryol. https://doi.org/10.1111/ahe.12765 (2021).
Tonar, Z., Egger, G. F., Witter, K. & Wolfesberger, B. Quantification of microvessels in canine lymph nodes. Microsc. Res. Tech. 71, 760–772 (2008).
Veselá, P., Tonar, Z., Sálek, D., Vokurka, S., Trněný, M., Kodet, R. et al. Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases. Virchows Arch. 465, 587–597 (2014).
Petrakis, G., Veloza, L., Clot, G., Gine, E., Gonzalez-Farre, B., Navarro, A. et al. Increased tumour angiogenesis in SOX11-positive mantle cell lymphoma. Histopathology 75, 704–714 (2019).
Gundersen, H. J. Estimators of the number of objects per area unbiased by edge effects. Microsc Acta 81, 107–117 (1978).
Forde, S., Matthews, J. D., Jahangiri, L., Lee, L. C., Prokoph, N., Malcolm, T. I. M. et al. Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy. Br. J. Haematol. 192, 354–365 (2021).
Woo, X. Y., Giordano, J., Srivastava, A., Zhao, Z. M., Lloyd, M. W., de Bruijn, R. et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat. Genet. 53, 86–99 (2021).
Choi, Y. Y., Lee, J. E., Kim, H., Sim, M. H., Kim, K. K., Lee, G. et al. Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci. Rep. 6, 22172 (2016).
Di Noia, J. M. & Neuberger, M. S. Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem. 76, 1–22 (2007).
Ben-David, U., Ha, G., Tseng, Y. Y., Greenwald, N. F., Oh, C., Shih, J. et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat. Genet. 49, 1567–1575 (2017).
Klanova, M., Soukup, T., Jaksa, R., Molinsky, J., Lateckova, L., Maswabi, B. C. et al. Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research. Lab. Invest. 94, 806–817 (2014).
